Ursprung des Netzwerks ersten Grades von Philip Taub
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
Reset Pharmaceuticals, Inc.
Reset Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Reset Pharmaceuticals, Inc. is a clinical-stage biotechnology company that focuses on developing and commercializing novel treatments for patients suffering from mental illness related to life-altering diseases. Reset Pharmaceuticals is based in Great Neck, NY and was founded by Philip Taub and Jan-Anders Karlsson. The company's lead product candidate, the oral psilocybin, is being developed to treat demoralization syndrome in patients with cancer. Reset Pharma has a highly experienced team with a strong track record of successful development, approvals, and launches of neuroscience drugs. The company also has a scientific advisory board of key opinion leaders in psychiatry, oncology, and psychedelics, as well as a strategic advisory board of business leaders and financial experts.
4
| Holding Company | Pharmaceuticals: Major | 4 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Philip Taub
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
VERONA PHARMA PLC | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
HealthPro BioVentures LLC
HealthPro BioVentures LLC Investment ManagersFinance Founded in 2003, HealthPro BioVentures LLC is a life sciences investment bank and strategic advisory firm headquartered in New York City | Investment Managers | Founder | |
University of Wisconsin | College/University | Undergraduate Degree | |
The Leonard N Stern School of Business | College/University | Masters Business Admin | |
Iona College | College/University | Undergraduate Degree | |
Ksana Health, Inc.
Ksana Health, Inc. Packaged SoftwareTechnology Services Ksana Health, Inc. is a mental health technology company based in Eugene, OR. Ksana Health aims to transform mental health care and research by translating tools and findings developed by the University of S Center for Digital Mental Health into digital products and services. Led by Dr. Nick Allen, a professor of clinical psychology, the company provides clients, practitioners, administrators, and researchers with digital tools that continuously measure behavioral health and offer personalized interventions to improve mental health. The company was founded in 2019 by Will Shortt and Nick Allen, who has been the CEO since incorporation. | Packaged Software | Director/Board Member | |
Tactogen, Inc.
Tactogen, Inc. Pharmaceuticals: MajorHealth Technology Tactogen, Inc. develops mental wellness medicines. The American company was founded in 2020 by Matthew Baggott and Luke A. Pustejovsky. Matthew Baggott has been the CEO since 2020. | Pharmaceuticals: Major | Consultant / Advisor | |
Palo Santo Investors-Qp LP | Founder | ||
Palo Santo Inc
Palo Santo Inc Investment ManagersFinance Palo Santo Inc (Palo Santo) is a venture capital firm founded in 2005 by Timothy J Schlidt and Daniel L. Goldberg. The firm is headquartered in New York. | Investment Managers | Founder | |
Bridge Investments LLC
Bridge Investments LLC Investment ManagersFinance Bridge Investments LLC (Bridge Investments) is a private equity and venture capital firm founded in 1998 by Robert Goldberg and Daniel Goldberg. The firm is headquartered in Chicago, Illinois. | Investment Managers | Private Equity Investor | |
Madison Dearborn Partners LLC
Madison Dearborn Partners LLC Investment ManagersFinance Madison Dearborn Partners LLC (Madison Dearborn Partners) is a private equity firm founded in 1992 by John A. Canning Jr., Paul J. Finnegan, Samuel M. Mencoff, Robin P. Selati, James N. Perry Jr. and Timothy P. Sullivan. The firm is headquartered in Chicago, Illinois. | Investment Managers | Private Equity Analyst | |
Bluestone Capital Partners LP
Bluestone Capital Partners LP Investment Banks/BrokersFinance Bluestone Capital Partners LP is a private company that provides brokerage services. The company is based in New York, NY. The company was founded by John H. Andreadis, Mark T. Behrman. | Investment Banks/Brokers | Founder | |
Opterion Health AG
Opterion Health AG Medical/Nursing ServicesHealth Services Opterion Health AG is a Swiss company that focuses on bringing innovation to dialysis care and fostering home dialysis to improve the quality of life for patients suffering from end-stage renal disease (ESRD). Opterion Health is based in Muttenz, CH. The private company aims to increase the survival rates of people with ESRD and reduce healthcare costs. The company was founded in 2012 by Guido Grentzmann, and the CEO is Bjorn Englund. | Medical/Nursing Services | Director/Board Member | |
University of Lund | College/University | Doctorate Degree | |
University of Uppsala | College/University | Graduate Degree | |
Bayer Pharmaceuticals Corp. | Chief Tech/Sci/R&D Officer | ||
S*BIO Pte Ltd.
S*BIO Pte Ltd. Pharmaceuticals: MajorHealth Technology S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. S*BIO has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize SB1518 and its other novel JAK2 inhibitor, SB1578. S*BIO's SB1317, a novel multikinase inhibitor, is in pre-clinical development and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization. In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include EDB Investments' biomedical sciences subsidiary Bio*One Capital, Aravis Ventures, Novartis Bioventures and other international funds. In 2009, S*BIO received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award. | Pharmaceuticals: Major | Chief Executive Officer | |
Columbia College (California) | College/University | Undergraduate Degree | |
AviadoBio Ltd.
AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | Biotechnology | Chief Executive Officer |
Statistik
International
Vereinigte Staaten | 16 |
Vereinigtes Königreich | 3 |
Schweden | 3 |
Schweiz | 2 |
Deutschland | 2 |
Sektoral
Health Technology | 7 |
Finance | 7 |
Consumer Services | 7 |
Technology Services | 2 |
Health Services | 2 |
Operativ
Director/Board Member | 10 |
Founder | 5 |
Corporate Officer/Principal | 5 |
Undergraduate Degree | 3 |
Chief Executive Officer | 3 |
Am stärksten vernetzte Beziehungen
- Börse
- Insiders
- Philip Taub
- Unternehmensverbindungen